Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy
Transplant Infectious Disease · 2023-11 · 25 (S1)
DOI: 10.1111/tid.14109 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant Infectious Disease, online erschienen am 29.07.2023. Verfasst von Gemma Reynolds und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Communicable Diseases, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Vaccines. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC, MRFF, National Health and Medical Research Council.
Abstract (Originalsprache)
Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to vaccine‐preventable infections. This review synthesizes national, international, and expert consensus vaccination schedules post‐HCT and presents evidence regarding the efficacy of newer vaccine formulations for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients with hematological malignancy. Revaccination post‐cellular therapies are less well defined. This review highlights important considerations around poor vaccine response, seroprevalence preservation after cellular therapies, and the optimal timing of revaccination. Future research should assess the immunogenicity and real‐world effectiveness of new vaccine formulations and/or vaccine schedules in patients post‐HCT and cellular therapy, including analysis of vaccine response that relates to the target of cellular therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.
ORCID-Profile: Gemma Reynolds, Victoria G Hall, Benjamin W Teh
Förderung
- NHMRC
- MRFF
- National Health and Medical Research Council
Zitieren
APA
Reynolds, G., Hall, V. G., & Teh, B. W. (2023). Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy. Transplant Infectious Disease, 25(S1). https://doi.org/10.1111/tid.14109
Vancouver
Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy. Transplant Infectious Disease. 2023;25(S1). doi:10.1111/tid.14109
BibTeX
@article{Reynolds2023,
author = {Reynolds, Gemma and Hall, Victoria G and Teh, Benjamin W},
title = {Vaccine schedule recommendations and updates for patients with hematologic malignancy post‐hematopoietic cell transplant or CAR T‐cell therapy},
journal = {Transplant Infectious Disease},
year = {2023},
volume = {25},
number = {S1},
doi = {10.1111/tid.14109}
}
EUVIMED